Xenpozyme

Xenpozyme (olipudase alfa) is an enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD). This prescription medication helps manage symptoms by replacing missing enzymes in the body. It is administered under medical supervision for long-term treatment.

Olipudase alfa is used to treat acid sphingomyelinase deficiency (ASMD), a rare genetic disorder. It helps reduce symptoms like enlarged liver and spleen, lung problems, and other complications. This therapy is designed to replace the missing enzyme in patients with ASMD. It is prescribed for long-term management of the condition.

Xenpozyme works by providing the missing enzyme to break down lipids in the body. Patients may experience improved organ function and reduced symptoms over time. The effects are typically monitored through regular medical evaluations to ensure safety and efficacy.

Xenpozyme is administered intravenously under medical supervision to monitor for reactions. Patients should discuss their full medical history, including allergies and current medications, with their healthcare provider. Regular monitoring is essential to manage potential side effects and ensure proper dosing.

Limited data exists on interactions with other medications. Patients should inform their doctor about all prescription, over-the-counter, and herbal products they use. Caution is advised when combining with other therapies that may affect liver or lung function.